Insights

Strategic AI platform CytoReason offers an AI-powered platform of computational disease models with a rich data backbone, enabling pharma and biotech customers to de-risk target discovery, indication prioritization, and patient stratification across drug development programs.

CNS and expanded data The company has broadened disease-model coverage to central nervous system indications and is expanding proprietary molecular and clinical data, presenting opportunities to upsell to sponsors aiming to deepen their data assets and model fidelity.

High-profile partnerships Recent and ongoing collaborations with industry leaders and investors (Pfizer, Thermo Fisher Scientific, NVIDIA, OurCrowd) signal credibility and potential for co-development deals, data sharing arrangements, and expanded use cases within large pharma pipelines.

US hub growth Plans to establish a Cambridge, Massachusetts office and scale operations in the United States align with a sales approach targeting US-based pharma and biotech customers seeking local support, regulatory familiarity, and accelerated onboarding.

Rapid product expansion Launch of LINA AI chat assistant and ongoing platform enhancements indicate a fast-moving product roadmap with opportunities to cross-sell advisory services, implementation packages, and training to maximize value realization for research teams.

Similar companies to CytoReason

CytoReason Tech Stack

CytoReason uses 8 technology products and services including Tableau, Apache Airflow, Kubernetes, and more. Explore CytoReason's tech stack below.

Media & News

CytoReason's Email Address Formats

CytoReason uses at least 2 email formats:
CytoReason Email FormatsExamplePercentage
First.Last@cytoreason.comJohn.Doe@cytoreason.com
90%
First@cytoreason.comJohn@cytoreason.com
10%

Frequently Asked Questions

What is CytoReason's official website and social media links?

Minus sign iconPlus sign icon
CytoReason's official website is cytoreason.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does CytoReason generate?

Minus sign iconPlus sign icon
As of October 2026, CytoReason's annual revenue is estimated to be $25M - $50M.

What is CytoReason's SIC code and NAICS code?

Minus sign iconPlus sign icon
CytoReason's SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does CytoReason have currently?

Minus sign iconPlus sign icon
As of October 2026, CytoReason has approximately 103 employees across 3 continents, including Asia, North America and Europe. Key team members include Chief Information Security Officer: A. T., Chief Operating Officer: E. S. and Chief Medical Officer: Y. C. Explore CytoReason's employee directory with LeadIQ.

What industry does CytoReason belong to?

Minus sign iconPlus sign icon
CytoReason operates in the Biotechnology Research industry.

What technology does CytoReason use?

Minus sign iconPlus sign icon
CytoReason's tech stack includes Tableau, Apache Airflow, Kubernetes, Figma, OpenAI, Auth0, Google Cloud and WP Engine.

What is CytoReason's email format?

Minus sign iconPlus sign icon
CytoReason's email format typically follows the pattern of First.Last@cytoreason.com. Find more CytoReason email formats with LeadIQ.

How much funding has CytoReason raised to date?

Minus sign iconPlus sign icon
As of October 2026, CytoReason has raised $100M in funding. The last funding round occurred on Jul 17, 2024 for $80M.

When was CytoReason founded?

Minus sign iconPlus sign icon
CytoReason was founded in 2016.
CytoReason logo

CytoReason

Biotechnology ResearchTel Aviv, Israel51-200 Employees

CytoReason is a biotechnology research company based in Tel Aviv, Israel that applies artificial intelligence to improve decision-making in drug development. It maintains an extensive database of public and proprietary data to map human diseases at tissue- and cell-level detail. The platform supports researchers across the drug development lifecycle by helping them identify targets, prioritize indications, and stratify patient populations, while program leaders can compare drugs across diseases or within a single disease and executives gain tools to manage portfolios.

CytoReason operates in the biotechnology research space, serving biopharma scientists, program leaders, and executives who rely on data-driven insights to advance candidate therapies. In 2026, the company announced an AI chat-style assistant for pharmaceutical R&D during the JPM HealthCare Conference, reflecting an expansion of its practical tools for research teams.

Section iconCompany Overview

SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2016
Employees
51-200

Section iconFunding & Financials

  • $100M

    CytoReason has raised a total of $100M of funding over 4 rounds. Their latest funding round was raised on Jul 17, 2024 in the amount of $80M as a Series B.

  • $25M - $50M

    CytoReason's revenue is estimated to be in the range of $25M - $50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.